Dopamine receptor antagonist
Dopaminergic blockers
Drug class
Haloperidol
Class identifiers
UseSchizophrenia, bipolar disorder, nausea and vomiting, etc.
ATC codeN05A
Biological targetDopamine receptors
External links
MeSHD012559
Legal status
In Wikidata

A dopamine antagonist, also known as an anti-dopaminergic and a dopamine receptor antagonist (DRA), is a type of drug which blocks dopamine receptors by receptor antagonism. Most antipsychotics are dopamine antagonists, and as such they have found use in treating schizophrenia, bipolar disorder, and stimulant psychosis.[1] Several other dopamine antagonists are antiemetics used in the treatment of nausea and vomiting.

Receptor pharmacology

Dopamine receptor flow chart

Dopamine receptors are all G protein–coupled receptors, and are divided into two classes based on which G-protein they are coupled to.[2] The D1-like class of dopamine receptors is coupled to Gαs/olf and stimulates adenylate cyclase production, whereas the D2-like class is coupled to Gαi/o and thus inhibits adenylate cyclase production.[2]

D1-like receptors: D1 and D5

D1-like receptors – D1 and D5 are always found post-synaptically. The genes coding these receptors lack introns, so there are no splice variants.

D1 receptors

D5 receptors

D2-like receptors: D2, D3 and D4

D2-like receptors unlike the D1-like class, these receptors are found pre and post-synaptically. The genes that code these receptors have introns, leading to many alternately spliced variants.

D2 receptors

D3 receptors

D4 receptors

Implications in disease

The dopaminergic system has been implicated in a variety of disorders. Parkinson's disease results from loss of dopaminergic neurons in the striatum.[5] Furthermore, most effective antipsychotics block D2 receptors, suggesting a role for dopamine in schizophrenia.[5][6][7] Additional studies hypothesize dopamine dysregulation is involved in Huntington's disease, ADHD, Tourette's syndrome, major depression, manic depression, addiction, hypertension and kidney dysfunction.[5][7][8] Dopamine receptor antagonists are used for some diseases such as schizophrenia, bipolar disorder, nausea and vomiting.[5]

Side effects

They may include one or more of the following and last indefinitely even after cessation of the dopamine antagonist, especially after long-term or high-dosage use:

Examples

First-generation antipsychotics (typical)

First generation antipsychotics are used to treat schizophrenia and are often accompanied by extrapyramidal side effects.[19] They inhibit dopaminergic neurotransmission in the brain by blocking about 72% of the D2 dopamine receptors.[20] They can also block noradrenergic, cholinergic, and histaminergic activity.[20]

Chemical Structure of typical antipsychotic chlorpromazine

Second-generation antipsychotics (atypical)

These drugs are not only dopamine antagonists at the receptor specified, but also act on serotonin receptor 5HT2A.[20][25] These drugs have fewer extrapyramidal side effects and are less likely to affect prolactin levels when compared to typical antipsychotics.[26]

Clozapine

Dopamine antagonists used to treat nausea and vomiting

Antagonists used only in research settings

References

  1. ^ Beaulieu JM, Gainetdinov RR (March 2011). "The physiology, signaling, and pharmacology of dopamine receptors". Pharmacological Reviews. 63 (1): 182–217. doi:10.1124/pr.110.002642. PMID 21303898. S2CID 2545878.
  2. ^ a b c d e f g h i j k l m Beaulieu JM, Gainetdinov RR (March 2011). "The physiology, signaling, and pharmacology of dopamine receptors". Pharmacological Reviews. 63 (1): 182–217. doi:10.1124/pr.110.002642. PMID 21303898. S2CID 2545878.
  3. ^ a b Sokoloff P, Diaz J, Le Foll B, Guillin O, Leriche L, Bezard E, Gross C (February 2006). "The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders". CNS & Neurological Disorders Drug Targets. 5 (1): 25–43. doi:10.2174/187152706784111551. PMID 16613552.
  4. ^ a b c d e f Missale C, Nash SR, Robinson SW, Jaber M, Caron MG (January 1998). "Dopamine receptors: from structure to function". Physiological Reviews. 78 (1): 189–225. doi:10.1152/physrev.1998.78.1.189. PMID 9457173.
  5. ^ a b c d Beaulieu JM, Gainetdinov RR (March 2011). "The physiology, signaling, and pharmacology of dopamine receptors". Pharmacological Reviews. 63 (1): 182–217. doi:10.1124/pr.110.002642. PMID 21303898. S2CID 2545878.
  6. ^ Seeman P (August 2006). "Targeting the dopamine D2 receptor in schizophrenia". Expert Opinion on Therapeutic Targets. 10 (4): 515–31. doi:10.1517/14728222.10.4.515. PMID 16848689. S2CID 30902536.
  7. ^ a b Missale C, Nash SR, Robinson SW, Jaber M, Caron MG (January 1998). "Dopamine receptors: from structure to function". Physiological Reviews. 78 (1): 189–225. doi:10.1152/physrev.1998.78.1.189. PMID 9457173.
  8. ^ Iversen SD, Iversen LL (May 2007). "Dopamine: 50 years in perspective". Trends in Neurosciences. 30 (5): 188–93. doi:10.1016/j.tins.2007.03.002. PMID 17368565. S2CID 22686973.
  9. ^ Zisapel N (December 2001). "Melatonin-dopamine interactions: from basic neurochemistry to a clinical setting". Cellular and Molecular Neurobiology. 21 (6): 605–16. doi:10.1023/A:1015187601628. PMID 12043836. S2CID 25508148.
  10. ^ Willis GL (2008). "Parkinson's disease as a neuroendocrine disorder of circadian function: dopamine-melatonin imbalance and the visual system in the genesis and progression of the degenerative process". Reviews in the Neurosciences. 19 (4–5): 245–316. doi:10.1515/revneuro.2008.19.4-5.245. PMID 19145986. S2CID 29375454.
  11. ^ a b c d e f Young SL, Taylor M, Lawrie SM (April 2015). ""First do no harm." A systematic review of the prevalence and management of antipsychotic adverse effects". Journal of Psychopharmacology. 29 (4): 353–62. doi:10.1177/0269881114562090. PMID 25516373. S2CID 8345032.
  12. ^ a b c Arana GW (2000). "An overview of side effects caused by typical antipsychotics". The Journal of Clinical Psychiatry. 61 (Suppl 8): 5–11, discussion 12–3. PMID 10811237.
  13. ^ a b c d e f g h i Divac N, Prostran M, Jakovcevski I, Cerovac N (2014). "Second-generation antipsychotics and extrapyramidal adverse effects". BioMed Research International. 2014: 656370. doi:10.1155/2014/656370. PMC 4065707. PMID 24995318.
  14. ^ a b c d Missale C, Nash SR, Robinson SW, Jaber M, Caron MG (January 1998). "Dopamine receptors: from structure to function". Physiological Reviews. 78 (1): 189–225. doi:10.1152/physrev.1998.78.1.189. PMID 9457173.
  15. ^ Nadal R (2001). "Pharmacology of the atypical antipsychotic remoxipride, a dopamine D2 receptor antagonist". CNS Drug Reviews. 7 (3): 265–82. doi:10.1111/j.1527-3458.2001.tb00199.x. PMC 6741677. PMID 11607043.
  16. ^ a b c Deng C (September 2013). "Effects of antipsychotic medications on appetite, weight, and insulin resistance". Endocrinology and Metabolism Clinics of North America. 42 (3): 545–63. doi:10.1016/j.ecl.2013.05.006. PMID 24011886.
  17. ^ Mortimer AM (March 2004). "How do we choose between atypical antipsychotics? The advantages of amisulpride". The International Journal of Neuropsychopharmacology. 7 Suppl 1 (5): S21-5. doi:10.1017/S1461145704004134. PMID 14972081.
  18. ^ a b Berman, Brian (January 2011). "Neuroleptic Malignant Syndrome". The Neuro Hospitalists. 1 (1): 41–47. doi:10.1177/1941875210386491. PMC 3726098. PMID 23983836.
  19. ^ a b c d e f g h i j k l m n o Beaulieu JM, Gainetdinov RR (March 2011). "The physiology, signaling, and pharmacology of dopamine receptors". Pharmacological Reviews. 63 (1): 182–217. doi:10.1124/pr.110.002642. PMID 21303898. S2CID 2545878.
  20. ^ a b c Chokhawala, Krutika (2 October 2021). "Antipsychotic Medications". StatPearls. PMID 30137788 – via NCBI.
  21. ^ a b Leucht S, Hartung B (April 2005). "Benperidol for schizophrenia". The Cochrane Database of Systematic Reviews. 2005 (2): CD003083. doi:10.1002/14651858.CD003083.pub2. PMC 7017029. PMID 15846648.
  22. ^ a b c d e f g h Sokoloff P, Diaz J, Le Foll B, Guillin O, Leriche L, Bezard E, Gross C (February 2006). "The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders". CNS & Neurological Disorders Drug Targets. 5 (1): 25–43. doi:10.2174/187152706784111551. PMID 16613552.
  23. ^ a b Missale C, Nash SR, Robinson SW, Jaber M, Caron MG (January 1998). "Dopamine receptors: from structure to function". Physiological Reviews. 78 (1): 189–225. doi:10.1152/physrev.1998.78.1.189. PMID 9457173.
  24. ^ a b c Beach, Scott (2013). "QTc prolongation, torsades de pointes, and psychotropic medications". The Academy of Psychosomatic Medicine. 54 (1): 1–13. doi:10.1016/j.psym.2012.11.001. PMID 23295003.
  25. ^ a b c Beaulieu JM, Gainetdinov RR (March 2011). "The physiology, signaling, and pharmacology of dopamine receptors". Pharmacological Reviews. 63 (1): 182–217. doi:10.1124/pr.110.002642. PMID 21303898. S2CID 2545878.
  26. ^ Nadal R (2001). "Pharmacology of the atypical antipsychotic remoxipride, a dopamine D2 receptor antagonist". CNS Drug Reviews. 7 (3): 265–82. doi:10.1111/j.1527-3458.2001.tb00199.x. PMC 6741677. PMID 11607043.
  27. ^ Sokoloff P, Diaz J, Le Foll B, Guillin O, Leriche L, Bezard E, Gross C (February 2006). "The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders". CNS & Neurological Disorders Drug Targets. 5 (1): 25–43. doi:10.2174/187152706784111551. PMID 16613552.
  28. ^ Mortimer AM (March 2004). "How do we choose between atypical antipsychotics? The advantages of amisulpride". The International Journal of Neuropsychopharmacology. 7 Suppl 1 (5): S21-5. doi:10.1017/S1461145704004134. PMID 14972081.
  29. ^ Stoner SC, Pace HA (May 2012). "Asenapine: a clinical review of a second-generation antipsychotic". Clinical Therapeutics. 34 (5): 1023–40. doi:10.1016/j.clinthera.2012.03.002. PMID 22494521.
  30. ^ Scheidemantel T, Korobkova I, Rej S, Sajatovic M (2015-12-04). "Asenapine for bipolar disorder". Neuropsychiatric Disease and Treatment. 11: 3007–17. doi:10.2147/NDT.S78043. PMC 4675633. PMID 26674884.
  31. ^ a b Yang CS, Huang H, Zhang LL, Zhu CR, Guo Q (July 2015). "Aripiprazole for the treatment of tic disorders in children: a systematic review and meta-analysis". BMC Psychiatry. 15: 179. doi:10.1186/s12888-015-0504-z. PMC 4518630. PMID 26220447.
  32. ^ Brown R, Taylor MJ, Geddes J (December 2013). "Aripiprazole alone or in combination for acute mania" (PDF). The Cochrane Database of Systematic Reviews (12): CD005000. doi:10.1002/14651858.CD005000.pub2. PMID 24346956.
  33. ^ Sokoloff P, Diaz J, Le Foll B, Guillin O, Leriche L, Bezard E, Gross C (February 2006). "The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders". CNS & Neurological Disorders Drug Targets. 5 (1): 25–43. doi:10.2174/187152706784111551. PMID 16613552.
  34. ^ a b Mortimer AM (March 2004). "How do we choose between atypical antipsychotics? The advantages of amisulpride". The International Journal of Neuropsychopharmacology. 7 Suppl 1 (5): S21-5. doi:10.1017/S1461145704004134. PMID 14972081.
  35. ^ Popovic D, Nuss P, Vieta E (2015-04-01). "Revisiting loxapine: a systematic review". Annals of General Psychiatry. 14: 15. doi:10.1186/s12991-015-0053-3. PMC 4391595. PMID 25859275.
  36. ^ Pollack CV (July 2016). "Inhaled loxapine for the urgent treatment of acute agitation associated with schizophrenia or bipolar disorder". Current Medical Research and Opinion. 32 (7): 1253–60. doi:10.1185/03007995.2016.1170004. PMID 27121764. S2CID 4402288.
  37. ^ Missale C, Nash SR, Robinson SW, Jaber M, Caron MG (January 1998). "Dopamine receptors: from structure to function". Physiological Reviews. 78 (1): 189–225. doi:10.1152/physrev.1998.78.1.189. PMID 9457173.
  38. ^ a b c d Sokoloff P, Diaz J, Le Foll B, Guillin O, Leriche L, Bezard E, Gross C (February 2006). "The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders". CNS & Neurological Disorders Drug Targets. 5 (1): 25–43. doi:10.2174/187152706784111551. PMID 16613552.
  39. ^ a b c d e f g Beaulieu JM, Gainetdinov RR (March 2011). "The physiology, signaling, and pharmacology of dopamine receptors". Pharmacological Reviews. 63 (1): 182–217. doi:10.1124/pr.110.002642. PMID 21303898. S2CID 2545878.
  40. ^ a b c d Mortimer AM (March 2004). "How do we choose between atypical antipsychotics? The advantages of amisulpride". The International Journal of Neuropsychopharmacology. 7 Suppl 1 (5): S21-5. doi:10.1017/S1461145704004134. PMID 14972081.
  41. ^ Asmal, Laila (2013). "Quetiapine versus other atypical antipsychotics for schizophrenia". Cochrane Database of Systematic Reviews (11): CD006625. doi:10.1002/14651858.CD006625.pub3. PMID 24249315.
  42. ^ a b Corena-McLeod M (June 2015). "Comparative Pharmacology of Risperidone and Paliperidone". Drugs in R&D. 15 (2): 163–74. doi:10.1007/s40268-015-0092-x. PMC 4488186. PMID 25943458.
  43. ^ Nadal R (2001). "Pharmacology of the atypical antipsychotic remoxipride, a dopamine D2 receptor antagonist". CNS Drug Reviews. 7 (3): 265–82. doi:10.1111/j.1527-3458.2001.tb00199.x. PMC 6741677. PMID 11607043.
  44. ^ Dose M, Lange HW (January 2000). "The benzamide tiapride: treatment of extrapyramidal motor and other clinical syndromes". Pharmacopsychiatry. 33 (1): 19–27. doi:10.1055/s-2000-7964. PMID 10721880. S2CID 260238868.
  45. ^ Stahl SM, Shayegan DK (2003). "The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice". The Journal of Clinical Psychiatry. 64 (Suppl 19): 6–12. PMID 14728084.
  46. ^ Tonini M, Cipollina L, Poluzzi E, Crema F, Corazza GR, De Ponti F (February 2004). "Review article: clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics". Alimentary Pharmacology & Therapeutics. 19 (4): 379–90. doi:10.1111/j.1365-2036.2004.01867.x. PMID 14871277.
  47. ^ a b c d Beaulieu JM, Gainetdinov RR (March 2011). "The physiology, signaling, and pharmacology of dopamine receptors". Pharmacological Reviews. 63 (1): 182–217. doi:10.1124/pr.110.002642. PMID 21303898. S2CID 2545878.
  48. ^ a b c Sokoloff P, Diaz J, Le Foll B, Guillin O, Leriche L, Bezard E, Gross C (February 2006). "The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders". CNS & Neurological Disorders Drug Targets. 5 (1): 25–43. doi:10.2174/187152706784111551. PMID 16613552.
  49. ^ a b Missale C, Nash SR, Robinson SW, Jaber M, Caron MG (January 1998). "Dopamine receptors: from structure to function". Physiological Reviews. 78 (1): 189–225. doi:10.1152/physrev.1998.78.1.189. PMID 9457173.
  50. ^ Martelle JL, Nader MA (2008). "A review of the discovery, pharmacological characterization, and behavioral effects of the dopamine D2-like receptor antagonist eticlopride". CNS Neuroscience & Therapeutics. 14 (3): 248–62. doi:10.1111/j.1755-5949.2008.00047.x. PMC 2753830. PMID 18801115.
  51. ^ Pagano G, Niccolini F, Politis M (June 2016). "Current status of PET imaging in Huntington's disease". European Journal of Nuclear Medicine and Molecular Imaging. 43 (6): 1171–82. doi:10.1007/s00259-016-3324-6. PMC 4844650. PMID 26899245.